Skip to main content

Market Overview

VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases

VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
  • VBI Vaccines Inc (NASDAQ: VBIVhas announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases.
  • The study was designed to compare the immunogenicity and safety of 10 µg of VBI's 3-antigen vaccine candidate to 20 µg of the single-antigen HBV vaccine, Engerix-B, made by GlaxoSmithKline Plc (NYSE: GSK).
  • Results from this Phase 3 study include:
  • The seroprotection rate (SPR), defined as the percent of participants who achieved antibody (anti-HBs) titers above the protective threshold of 10 mIU/mL in patients over 45 years of age, was 91.4% for VBI's vaccine compared to 76.5% for Engerix-B at Day 196.
  • The SPR in adults over 45 years was 89.4% for VBI's vaccine vs. 73.1% for Engerix-B at Day 196, exceeding the pre-set margins for statistical superiority and clinical superiority.
  • In adults age 18-44 years, the SPR after two doses (Day 168) of VBI's vaccine was comparable to three doses of Engerix-B (Day 196) – 87.2% vs. 91.1%, respectively.
  • In all participants, VBI's vaccine elicited 6x higher Geometric Mean Concentration (GMC) of anti-HBs titers (1148.2 mIU/mL vs. 192.6 mIU/mL).
  • No safety signals were observed in either vaccine arm, and no new safety risks were identified.
  • Price Action: VBIV shares are trading 4.01% higher at $2.85 on the last check Wednesday.

Related Articles (GSK + VBIV)

View Comments and Join the Discussion!

Posted-In: Briefs Hepatits BBiotech News Penny Stocks Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at